Recombinant ITGAL (Efalizumab Biosimilar) anticorps

N° du produit ABIN7795106

Cet anticorps Souris Monoclonal détecte spécifiquement ITGAL (Efalizumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.

Aperçu rapide pour Recombinant ITGAL (Efalizumab Biosimilar) anticorps (ABIN7795106)

Antigène: ITGAL (Efalizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp ITGAL (Efalizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-ITGAL (Efalizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Efalizumab Biosimilar, CD11a Monoclonal Antibody

Attributs du produit: Efalizumab Biosimilar uses the same protein sequences as the therapeutic antibody efalizumab. Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human CD11a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur ITGAL (Efalizumab Biosimilar)

Antigène: ITGAL (Efalizumab Biosimilar)

Autre désignation: Efalizumab Biosimilar

Classe de substances: Biosimilar